-
EP1675873
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1675873
| EP1675873 - CORRELATION BETWEEN THE FUCOSE CONTENT / GALACTOSE CONTENT RATIO OF ANTI-RHESUS-D AND ANTI-HLA-DR ANTIBODIES AND THE ADCC ACTIVITY [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 11.11.2011 Database last updated on 22.08.2024 | Most recent event Tooltip | 18.11.2011 | New entry: Date of cancellation oral proceedings | Applicant(s) | For all designated states LFB Biotechnologies 3 Avenue des Tropiques ZA de Courtaboeuf 91940 Les Ulis / FR | [2008/19] |
| Former [2006/27] | For all designated states Laboratoire Français du Fractionnement et des Biotechnologies Zone d'Activité de Courtaboeuf, 3, avenue des Tropiques 91940 Les Ulis / FR | Inventor(s) | 01 /
BIHOREAU, Nicolas 36, avenue Parrat F-91400 Orsay / FR | 02 /
DE ROMEUF, Christophe 116, rue de la Bassée 59000 Lille / FR | 03 /
JORIEUX, Sylvie 17, rue Molière F-59650 Villeneuve d'Ascq / FR | 04 /
NONY, Emmanuel 59, rue Pajeaud F-92160 Antony / FR | 05 /
BOUREL, Dominique 35, avenue Germaine F-59110 La Madeleine / FR | [2006/27] | Representative(s) | Warcoin, Jacques Cabinet Regimbeau 20, rue de Chazelles 75847 Paris Cedex 17 / FR | [N/P] |
| Former [2006/27] | Warcoin, Jacques Cabinet Régimbeau 20, rue de Chazelles 75847 Paris cedex 17 / FR | Application number, filing date | 04805250.0 | 20.10.2004 | [2006/27] | WO2004FR02686 | Priority number, date | FR20030012229 | 20.10.2003 Original published format: FR 0312229 | [2006/27] | Filing language | FR | Procedural language | FR | Publication | Type: | A1 Application with search report | No.: | WO2005040221 | Date: | 06.05.2005 | Language: | FR | [2005/18] | Type: | A1 Application with search report | No.: | EP1675873 | Date: | 05.07.2006 | Language: | FR | The application published by WIPO in one of the EPO official languages on 06.05.2005 takes the place of the publication of the European patent application. | [2006/27] | Search report(s) | International search report - published on: | EP | 06.05.2005 | Classification | IPC: | C07K16/34, C07K16/00, A61P31/00, A61P35/00, A61P37/06, C12N5/12, A61K39/395, C07K16/28 | [2006/27] | CPC: |
C07K16/00 (EP,US);
A61P11/06 (EP);
A61P29/00 (EP);
A61P31/00 (EP);
A61P31/06 (EP);
A61P31/12 (EP);
A61P33/00 (EP);
A61P33/12 (EP);
A61P35/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P7/04 (EP);
C07K16/2833 (EP,US);
C07K16/34 (EP,US);
A61K2039/505 (EP,US);
C07K2317/21 (EP,US);
C07K2317/24 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/27] | Extension states | AL | Not yet paid | HR | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | Title | German: | KORRELATION ZWISCHEN DEM FUCOSEGEHALT/ GALACTOSEGEHALT-VERHÄLTNIS VON ANTI-RHESUS-D- UND ANTI-HLA-DR-ANTIKÖRPERN UND DER ADCC-AKTIVITÄT | [2006/27] | English: | CORRELATION BETWEEN THE FUCOSE CONTENT / GALACTOSE CONTENT RATIO OF ANTI-RHESUS-D AND ANTI-HLA-DR ANTIBODIES AND THE ADCC ACTIVITY | [2006/27] | French: | CORRELATION DU RATIO TAUX DE FUCOSE / TAUX DE GALACTOSE D'ANTICORPS ANTI RHESUS D ET ANTI HLA-DR AVEC L'ACTIVITE ADCC | [2006/27] | Entry into regional phase | 31.03.2006 | National basic fee paid | 31.03.2006 | Designation fee(s) paid | 31.03.2006 | Examination fee paid | Examination procedure | 31.03.2006 | Examination requested [2006/27] | 09.10.2008 | Despatch of a communication from the examining division (Time limit: M06) | 04.02.2009 | Reply to a communication from the examining division | 31.07.2009 | Despatch of a communication from the examining division (Time limit: M06) | 18.01.2010 | Reply to a communication from the examining division | 04.11.2011 | Application withdrawn by applicant [2011/50] | 07.11.2011 | Cancellation of oral proceeding that was planned for 01.12.2011 | 01.12.2011 | Date of oral proceedings (cancelled) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 09.10.2008 | Fees paid | Renewal fee | 31.03.2006 | Renewal fee patent year 03 | 15.10.2007 | Renewal fee patent year 04 | 26.03.2008 | Renewal fee patent year 05 | 19.10.2009 | Renewal fee patent year 06 | 18.10.2010 | Renewal fee patent year 07 | 17.10.2011 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]EP0316463 (UNIV NORTHWESTERN [US]) [A] 14,36* page 3 *; | [XY]WO0177181 (LAB FRANCAIS DU FRACTIONNEMENT [FR], et al) [X] 1-25,27-35,37-57 * page 1, line 7 * * page 3, line 20 - page 5, line 16 * * table 3 * [Y] 36; | [DXY] - SHINKAWA T ET AL, "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (20030131), vol. 278, no. 5, ISSN 0021-9258, pages 3466 - 3473, XP002965857 [DX] 1-25,27-35,37-57 * page 3466, column L * * page 3471, column L, paragraph LAST - page 3473, column L, paragraph 1 * [Y] 36 DOI: http://dx.doi.org/10.1074/jbc.M210665200 | [DX] - SHIELDS R L ET AL, "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, (20020726), vol. 277, no. 30, ISSN 0021-9258, pages 26733 - 26740, XP002964542 [DX] 1-25,27-57 * the whole document * DOI: http://dx.doi.org/10.1074/jbc.M202069200 | [DA] - WRIGHT A ET AL, "Effect of glycosylation on antibody function: implications for genetic engineering", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (1997), vol. 15, no. 1, ISSN 0167-7799, pages 26 - 32, XP004016809 [DA] 1-25,27-57 * page 29, column L, paragraph 2 - column R * DOI: http://dx.doi.org/10.1016/S0167-7799(96)10062-7 | [DA] - DAVIES J ET AL, "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII", BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, (20010820), vol. 74, no. 4, ISSN 0006-3592, pages 288 - 294, XP002285964 [DA] 1-25,27-57 * abstract * DOI: http://dx.doi.org/10.1002/bit.1119 | [DA] - UMANA P ET AL, "ENGINEERED GLYCOFORMS OF AN ANTINEUROBLASTOMA IGG1 WITH OPTIMIZED ANTIBODY-DEPENDENT CELLULAR CYTOTOXIC ACTIVITY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, (199902), vol. 17, ISSN 1087-0156, pages 176 - 180, XP002921620 [DA] 1-25,27-57 * page 176, column L, paragraph 2 - column R, paragraph 2; figure 1 * DOI: http://dx.doi.org/10.1038/6179 | Examination | - MORI KATSUHIRO ET AL, "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.", CYTOTECHNOLOGY DEC 2007 LNKD- PUBMED:19003000, (200712), vol. 55, no. 2-3, ISSN 0920-9069, pages 109 - 114, XP019550382 DOI: http://dx.doi.org/10.1007/s10616-007-9103-2 | - B. M. Kumpel, "Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers", Vox Sanguinis, (20070801), vol. 93, no. 2, doi:10.1111/j.1423-0410.2007.00945.x, ISSN 0042-9007, pages 99 - 111, XP055002584 DOI: http://dx.doi.org/10.1111/j.1423-0410.2007.00945.x |